StockNews.com Initiates Coverage on Invitae (NYSE:NVTA)

Research analysts at StockNews.com initiated coverage on shares of Invitae (NYSE:NVTA) in a report issued on Wednesday. The firm set a “hold” rating on the medical research company’s stock.

Invitae Price Performance

Shares of NYSE:NVTA opened at $0.00 on Wednesday. The firm has a market cap of $213,608.00, a PE ratio of 0.00 and a beta of 1.59. Invitae has a 52-week low of $0.02 and a 52-week high of $0.02.

Institutional Trading of Invitae

A number of institutional investors and hedge funds have recently bought and sold shares of NVTA. Janney Montgomery Scott LLC grew its holdings in Invitae by 404.6% during the 3rd quarter. Janney Montgomery Scott LLC now owns 63,105 shares of the medical research company’s stock worth $38,000 after acquiring an additional 50,600 shares during the period. HighTower Advisors LLC grew its holdings in Invitae by 14.1% during the 3rd quarter. HighTower Advisors LLC now owns 600,354 shares of the medical research company’s stock worth $339,000 after acquiring an additional 74,405 shares during the period. Financial Gravity Asset Management Inc. grew its holdings in Invitae by 1,799.5% during the 3rd quarter. Financial Gravity Asset Management Inc. now owns 73,929 shares of the medical research company’s stock worth $45,000 after acquiring an additional 70,037 shares during the period. Green Alpha Advisors LLC grew its holdings in Invitae by 138.4% during the 4th quarter. Green Alpha Advisors LLC now owns 452,585 shares of the medical research company’s stock worth $284,000 after acquiring an additional 262,760 shares during the period. Finally, SG Americas Securities LLC grew its holdings in Invitae by 90.7% during the 4th quarter. SG Americas Securities LLC now owns 91,937 shares of the medical research company’s stock worth $58,000 after acquiring an additional 43,717 shares during the period. 61.28% of the stock is currently owned by institutional investors and hedge funds.

About Invitae

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.